Forte Total Stockholder Equity from 2010 to 2024

FBRX Stock  USD 21.71  1.92  9.70%   
Forte Biosciences Total Stockholder Equity yearly trend continues to be fairly stable with very little volatility. Total Stockholder Equity is likely to outpace its year average in 2024. Total Stockholder Equity is the total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders. View All Fundamentals
 
Total Stockholder Equity  
First Reported
2017-03-31
Previous Quarter
17 M
Current Value
9.4 M
Quarterly Volatility
21.1 M
 
Covid
Check Forte Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Forte Biosciences' main balance sheet or income statement drivers, such as Interest Income of 1.3 M, Depreciation And Amortization of 8.6 K or Interest Expense of 14.5 K, as well as many indicators such as Price To Sales Ratio of 9.98, Dividend Yield of 0.0 or PTB Ratio of 0.7. Forte financial statements analysis is a perfect complement when working with Forte Biosciences Valuation or Volatility modules.
  
Check out the analysis of Forte Biosciences Correlation against competitors.
For more information on how to buy Forte Stock please use our How to Invest in Forte Biosciences guide.

Latest Forte Biosciences' Total Stockholder Equity Growth Pattern

Below is the plot of the Total Stockholder Equity of Forte Biosciences over the last few years. It is the total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders. Forte Biosciences' Total Stockholder Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Forte Biosciences' overall financial position and show how it may be relating to other accounts over time.
Total Stockholder Equity10 Years Trend
Very volatile
   Total Stockholder Equity   
       Timeline  

Forte Total Stockholder Equity Regression Statistics

Arithmetic Mean38,853,457
Coefficient Of Variation47.48
Mean Deviation10,540,749
Median39,083,000
Standard Deviation18,448,863
Sample Variance340.4T
Range75.9M
R-Value0.03
Mean Square Error366.3T
R-Squared0.0007
Significance0.92
Slope110,032
Total Sum of Squares4765T

Forte Total Stockholder Equity History

202442.2 M
202335.3 M
202238.8 M
202141.5 M
202059 M
2019-4.8 M
201858.1 M

About Forte Biosciences Financial Statements

Forte Biosciences investors use historical fundamental indicators, such as Forte Biosciences' Total Stockholder Equity, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Forte Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Stockholder Equity35.3 M42.2 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Forte Stock Analysis

When running Forte Biosciences' price analysis, check to measure Forte Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Forte Biosciences is operating at the current time. Most of Forte Biosciences' value examination focuses on studying past and present price action to predict the probability of Forte Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Forte Biosciences' price. Additionally, you may evaluate how the addition of Forte Biosciences to your portfolios can decrease your overall portfolio volatility.